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Background: Perfluorocarbon liquid (PCL)-perfused vitrectomy has been shown in previous 
studies to be feasible, safe, and to have advantages in managing complicated cases of tractional 
retinal detachment. The present study had the objectives of describing the anatomical results 
and measuring surgical time and PCL consumption when combining PCL-perfused techniques 
with modern vitrectomy equipment.
Methods: A prospective, interventional consecutive case series was investigated. We enrolled 
patients with diabetic tractional retinal detachment, complicated by proliferative vitreoretinopathy 
and poor vision. A 23 gauge PCL-perfused vitrectomy was done with three-dimensional settings. 
During the procedure, we assessed the degree of surgical bleeding, visualization quality, and 
difficulty of membrane dissections. Visual acuity, intraocular pressure, and anatomical success 
were assessed at one and 3 months of follow-up.
Results: Twelve patients were enrolled in this study. There were no statistical significant 
changes in intraocular pressure and visual acuity throughout the follow-up period. Surgery 
was performed in a hemorrhage-free environment in almost all cases, with good visualization 
and low technical difficulty. The mean complete surgical time was 94.92 ± 25.03 minutes. The 
mean effective   vitrectomy time was 22.50 ± 19.04 minutes and the mean PCL consumption was 
25.08 ± 9.76 mL, with a speed of 1.11 mL/minute. Anatomical success was 67% at 3 months.
Conclusion: Although the technique proved to have some advantages in managing   complicated 
cases of diabetic tractional retinal detachment, there was a high consumption of PCL. A rede-
sign of the entire system is needed in order to decrease the amount of PCL needed for the 
technique.
Keywords: retinal detachment, diabetic, surgery, vitrectomy, vitreoretinopathy, perfluorocarbon
Introduction
Tractional retinal detachment is one of the major causes of severe visual loss in patients 
with proliferative diabetic retinopathy.1–3 In about 5%–10% of cases, proliferative 
  vitreoretinopathy develops and complicates the anatomical and functional prognosis.4,5 
Despite advances in surgical instrumentation and techniques, management of advanced 
cases of tractional retinal detachment, with or without proliferative vitreoretinopathy, 
continues to demand a mixture of surgical skill, experience, and good judgment.6,7
Vitrectomy techniques are very challenging in such cases. The vitreous body can 
be either transparent, making it difficult to identify and ensure its complete removal, or 
a dense vitreous hemorrhage can be encountered, precluding satisfactory   visualization 
of intraocular structures, increasing the risk of iatrogenic damage.1,8   During 





The   consequences of not doing so can range from poor 
visualization of the fundus (making the following surgical 
steps more difficult) to a complete failure of the surgery 
(uncontrollable bleeding).4,8,10 Usually, the formation of 
new clots generates “sticky” pseudomembranes that adhere 
very firmly to the healthy retina or to neovascular or fibrous 
proliferations, making it very hard to remove without doing 
retinotomies or causing more bleeding. However, the maneu-
ver that probably demands more surgical expertise in com-
plicated cases of tractional retinal detachment is dissection 
of the posterior hyaloid and fibrovascular membranes from 
attached or detached retina, because most of the time having a 
refined surgical technique is not sufficient.1,2,8 Surgeons must 
also have a complete and comprehensive understanding of 
the disease in order to succeed.
Since its introduction by Chang et al in 1987, the use of 
perfluorocarbon liquids (PCLs) as surgical adjuvants has 
spread throughout the world and currently forms part of every 
retina practice.11–14 PCLs are fluorinated carbon molecules, 
with a high affinity for oxygen. They are colorless and odor-
less substances with low viscosity.13 Their index of refraction 
is slightly different from that of saline, which allows good 
visibility. Perhaps their most important properties are their 
high density that helps flatten and stabilize the detached retina 
during surgery as well as their immiscibility with blood and 
other cellular debris.13–15
In a previous report, we described a surgical technique in 
which we used PCL as an infusion substance instead of regular 
saline.14 The advantages identified in this procedure were: its 
high oxygen-carrying capacity, which may be useful during sur-
gery on an ischemic retina; oxygen affinity, which may facilitate 
elevation of intraocular pressure, allowing a hemorrhage-free 
surgery; immiscibility of PCL with blood and debris, which 
may facilitate surgery and improve surgical   efficiency; and 
the high density of PCL, which may help to reattach and sta-
bilize the retina during vitrectomy and membrane peeling.14,15 
However, regardless of the aforementioned advantages, the 
original technique was described using vitrectomy probes of 
existing caliber (20 gauge) and available vitrectomy machines. 
Fluid control was extremely inefficient, and large losses of 
PCL during surgery were encountered. Therefore, a consid-
erable amount of PCL was required to perform the surgery, 
transforming it into a less than cost-effective procedure.14 In 
a second report, we described the use of 25 gauge vitrectomy 
in order to minimize PCL loss during surgery, and although 
we were successful in reducing the amount of PCL required 
for the technique (up to 70% less) and had good anatomical 
results, the amounts were still too high.16
The present study has the aim of describing the feasibility 
and anatomical results of PCL perfused vitrectomy combined 
with dual dynamic drive software (three-dimensional, Alcon 
Laboratories, Fort Worth, TX) and 23 gauge vitrectomy with 
Eckardt valves in complicated cases of tractional retinal 
detachment, as well as measuring surgical time and compar-
ing PCL consumption with previous studies by combining 
these technologies.
Materials and methods
A prospective, interventional consecutive case series was 
designed. The study was approved by the internal review 
board of the Asociación para Evitar la Ceguera en Mexico 
Hospital. The study was conducted according to the tenets of 
the Declaration of Helsinki. All patients signed an informed 
consent before any procedure was done and after a detailed 
explanation, according to the level of education of each 
individual patient, had been made. The study was conducted 
in the hospital facilities and was funded completely by the 
hospital research fund.
We enrolled treatment-naive patients (surgery) with a 
clinical diagnosis of longstanding diabetic tractional retinal 
detachment, complicated by proliferative   vitreoretinopathy 
(grade C2 or higher, according to the Retina Society Clas-
sification)17,18 and best-corrected visual acuity of 20/200 
or worse, regardless of race, gender or previous retina 
  photocoagulation, who rejected preoperative use of intra-
vitreal bevacizumab despite a comprehensive explanation 
about its use. We excluded patients with previous filtration 
surgery, a clinical diagnosis of glaucoma, inflammatory eye 
disease, or with significant corneal, lens or other anterior 
chamber opacities that precluded fundus observations   during 
follow-up.
All patients underwent a complete   ophthalmological 
examination which included best-corrected visual   acuity 
  assessment using protocol Early Treatment Diabetic 
  Retinopathy Study refraction, intraocular pressure 
  measurement, and anterior chamber and fundus examina-
tion with indirect ophthalmoscopy. We followed the patients 
for a minimum of 3 months, and the follow-up appointments 
were at days 1, 30, and 90 after surgery. All measurements 
were repeated at every appointment.
surgical technique
The main surgical technique used has been described 
elsewhere.14,15 The general tubing settings are depicted 
in Figure 1. The main differences are the following. 







Figure 1 General diagram of PCL infusion system. (A) PCL container, (B and C) three-way valve, (D) saline container, (E) 23 gauge vitrectomy cassette, and (F) tractional 
retinal detachment. 
Abbreviation: VgFi, Vented Gas Forced InfusionTM (Alcon Laboratory, Fort Worth, TX).




23 gauge PCL for tractional retinal detachment
Surgical   System and XS4 fourth-generation software, three-
  dimensional technology (Alcon Laboratories) and an Eckard 
valve (Dutch Ophthalmic Research Center, Scheijdelveweg, 
Zuidland, The Netherlands) which has plastic tabs to prevent 
fluid loss during surgery. None of the patients received 
intravitreal bevacizumab prior to surgery. The surgical 
parameters were adjusted according to surgeon preference 
(HQM). The cuts per minute ranged between 2500 and 1500; 
the vacuum level was selected according to each individual 
case. The intraocular infusion pressure ranged between 25 to 
30 mmHg. The selection of surgical tamponade was done 
according to each case in particular. The assessment of sur-
gical bleeding and visualization quality was done by a third 
person (not related to the surgical procedure) by reviewing 
the digital videos of the surgery and graded according to 
subjective scales. Surgical bleeding was classified accord-
ing to its magnitude, ie, mild (did not prevent visualization 
and was easy to aspirate), moderate (prevented visualization 
for small periods of time but was still easy to aspirate), and 
severe (prevented visualization completely, blood located in 
the interface between PCL and balanced salt solution, and 
was hard or impossible to aspirate). The quality of retina 
visualization during surgery was classified according to a 
subjective system of five levels, ie, very good (if retinal 
fundus and its capillary vasculature could be identified), 
good (if retina fundus but only main retinal vasculature could 
be identified), fair (if only vascular proliferations and optic 
nerve, but no retina fundus could be identified), bad (if only 
the optic nerve or some proliferations could be identified), 
and very bad (if one could not identify any structure). The 
difficulty of the dissection of posterior hyaloid and fibrovas-
cular membranes was graded by the surgeon himself at the 
end of the surgery. Quantification of the amount of PCL used 
during the procedure was done by the second surgeon via 
recollecting the PCL from the vitrectomy cassette bag. The 
complete surgical time (from anesthesia to the placement of 
the eye patch) and the effective vitrectomy time (from inser-
tion of vitrectomy to end of vitreous removal) was drawn 
from the Accurus timer. Effective vitrectomy time included 
time spent on dissection of the posterior hyaloid but not time 
spent on dissecting fibrovascular membranes or vitreoretinal 
proliferation peeling.
The PCL used was perfluoro-N-octane (C3F18) with a 
viscosity of 0.8 CsT, refractive index of 1.27, and specific 
gravity of 1.76. PCL was purified and filtered under sterile 
conditions with a Millipore filter of 0.45 µm and 0.2 µm 
(Bedford, MA) and sterilized with ethylene oxide and placed 
in sterile containers. This form of PCL was not   commercially 
available at that time but was supplied with a medical 
  pureness degree by a private manufacturer (Vitreoretinal 
Technologies, Irving CA).
Statistical analysis was performed using SPSS   software 
version 10.1.0 (Sigma Stat; Systat Software Inc, San 
Jose, CA). Data are presented as the median and standard Clinical Ophthalmology 2011:5
Table 2 subjective surgery measurements
No Hemorrhage Visual quality Membrane peeling
 1 Moderated Vg Moderated
 2 Mild Vg Moderated
 3 Mild Vg easy
 4 Moderated g hard
 5 Mild g easy
 6 Mild g easy
 7 Mild Vg easy
 8 Mild Vg Moderated
 9 Mild g easy
10 Mild Vg ease
11 Mild Vg Moderated
12 Moderated Vg ease
Abbreviations: Vg, very good; g, good.
Table 3 surgical times
No CST (min) EVT (min) PCL (mL)
 1 92 31 30
 2 70 16 32
 3 54 12 23
 4 130 22 45
 5 85 18 8
 6 97 12 18
 7 116 24 21
 8 145 80 35
 9 80 14 18
10 92 11 20
11 90 17 30
12 88 13 21
Abbreviations: CST, complete surgery time; EVT, effective vitrectomy time; PCL, 
perfluorocarbon liquid consumption.
Table 1 Proliferative vitreoretinopathy classification, according 
to the Retina Society Classification






 1 48 M OFF C2,3 CF 1 m 20/800 20/800
 2 54 F OFF C2,4 hM CF 1 m 20/1000
 3 29 F OFF C3 hM hM hM
 4 55 M OFF C2,3 CF 1 m CF 1 m CF 1 m
 5 49 M On C2,3 20/400 20/400 20/320
 6 53 F OFF C4 CF 4 m CF 1 m CF 1 m
 7 57 F On C2 20/320 20/320 20/200
 8 48 M OFF C3 hM 20/800 20/320
 9 55 M OFF C2 CF 1 m 20/800 20/630
10 62 F OFF C3 CF 1 m 20/1000 20/800
11 56 F OFF C3,4 CF 1 m CF 1 m 20/800
12 611 F On C3 20/200 20/200 20/400
Abbreviations:  BCVA,  best-corrected  visual  acuity;  CF  1  m,  count  fingers  at 
1 meter; HM, hand movement; M, male; F, female.





  deviation. For data analysis, a two-tailed t-test was used. 
A P value , 0.05 was considered statistically significant.
Results
A total of 12 patients (seven females, 58.3%) were enrolled in 
the study. The demographic data are summarized in Table 1. 
The median age of the group was 52.25 ± 8.6 years. Of the 
12 patients, nine (75%) had the macula off at the time of 
enrollment. The median time between visual loss and reti-
nal surgery was 9.2 ± 2.5 (range 4–12) months. Most of the 
patients had C2 or C3 vitreoretinal proliferation; only two 
had C4 vitreoretinal proliferation (patients 2 and 11). The 
mean intraocular pressure at baseline was 14.54 ± 2.5 mmHg, 
18.5 ± 2.7 mmHg at one month, and 15.71 ± 1.8 mmHg at 
3 months of follow-up. There was no statistical difference 
regarding intraocular pressure. A summary of best-corrected 
visual acuity throughout the follow-up period is depicted in 
Table 1, and although there was a trend of improvement, 
there were no statistical differences (P = 0.07 at one month 
and P = 0.06 at 3 months).
Surgical characteristics regarding severity of hemorrhage, 
visual quality, and difficulty of membrane peeling are sum-
marized in Table 2. Most of the surgeries were performed in 
a hemorrhage-free environment (75%). Only three of them 
encountered moderate bleeding during surgery. Visual qual-
ity was labeled from “good” to “very good”, and the surgeon 
described the difficulty of membrane and posterior hyaloid 
peeling as easy to moderate.
Surgical times and PCL consumption are summarized 
in Table 3. Mean complete surgical time was 94.92 ± 25.03 
(range 54–145) minutes. Mean effective vitrectomy time was 
22.50 ± 19.04 (range 11–80) minutes. Mean PCL consump-
tion was 25.08 ± 9.76 mL, with an average consumption 
per minute of 1.11 mL of PCL. Silicon oil (5000 CsT) was 
used as surgical tamponade in all cases. Anatomical success 
was obtained in all cases after surgery but, after 3 months of 
follow-up, only eight patients (67%) had an attached retina. 
Of the remaining cases, two had small inferior detachment 
and were treated successfully with laser photocoagulation. 
The other two had significant inferior and superior detach-
ments due to reproliferation of vitreoretinal proliferation 
and required a second vitrectomy combined with a scleral 
buckle. Anatomical success was obtained in both cases after 
the second surgery. There were no complications related to 
the surgical technique.
Discussion
Since its introduction by Machemer in 1970, the indications 
for vitrectomy have been expanded tremendously and today 
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Its applications include vitreous hemorrhages, retinal 
  detachment, macular edema, macular holes, and vitreoretinal 
  interface abnormalities, among others.21–24 The adoption of 
PCL as a surgical tool has proved to be safe and nontoxic to 
the retina, even in cases of accidental retained droplets after 
vitrectomy or while used as a short-term tamponade.14,25,26 
In the present study, replacement of balanced salt solution 
with PCF as the infusion substance appears to be safe and 
helped with resolution of cases. The special physical prop-
erties of PCF allowed quick stabilization of the retina in a 
hemorrhage-free environment as well as quick reattachment 
while maintaining excellent visualization of the intraocular 
structures.
However, although there was improved fluid control, 
better surgical equipment, and updated software, the total 
amount of PCL consumed was still high and almost identical 
to that previously reported in the 25 gauge study (24.38 mL 
versus 25.08 mL). The speed of consumption was also very 
fast (1.11 mL/minute). Therefore, the cost-effectiveness of 
the procedure is still very poor. During review of the sys-
tem, we became aware that most of the PCL used is wasted 
on tubing and dead spaces in the system. Thus, the authors 
speculate that if they could design a system with a significant 
reduction in the length of the infusion line along with a spe-
cially designed bottle and recirculation device (which could 
separate cellular debris from PCL and perhaps oxygenate it 
at the same time), we could effectively decrease the amount 
of PCL needed for the technique and reduce the speed of 
consumption by up to 0.3 mL/minute. Perhaps then the cost 
of doing the surgery will be no obstacle to performing it more 
often and prospective studies with larger sample sizes and 
larger follow-up periods could be conducted.
Another option for reducing bleeding during vitrectomy 
is the use of intravitreal bevacizumab prior to surgery.1,27 
Studies have shown that a previous dose can decrease not 
only bleeding, but also the need of endodiathermy, need for 
frequent surgical tool exchange, and operative time, while 
increasing the number of blunt dissections against sharp dis-
sections, which is indirect evidence of a more straightforward 
procedure.1,27 The combination of intravitreal bevacizumab 
prior to surgery with a PCL-perfused technique could pose 
greater benefits than both techniques used separately. In this 
study, candidates were selected from patients who had actively 
refused use of preoperative bevacizumab after an explanation 
of possible cardiovascular and cerebrovascular side effects. 
As an alternative way to prevent massive bleeding during 
the procedure, we offered the surgical technique described 
above. Therefore, the low numbers of patients enrolled in this 
study could be explained by the rarity of the pathology and 
the reduced number of available patients for consent.
In two recent reports, Arevalo described a variation of this 
technique and named it “en bloc perfluorodissection”.28,29 In 
these reports, Arevalo acknowledged the special advantages of 
the technique and highlighted the capacity of PCL for dissect-
ing the posterior hyaloid from fibrovascular membranes. He 
also concurred about the improved visualization of vitreous 
and intraocular structures, the rapid retinal reattachment and 
quick resolution of subretinal fluid during surgery, and easier 
dissection of epiretinal membranes and posterior hyaloid in a 
PCL-filled vitreous cavity.28,29 An evident advantage of en bloc 
perfluorodissection over PCF-perfused vitrectomy would be 
the small amount of PCL required for en bloc perfluorodissec-
tion (mean 4 mL, range 3–8 mL). The author also expressed 
concerns about PCL pressing on the posterior hyaloid and 
fibrovascular tissue, increasing the degree of difficulty of its 
dissection.28,29 However, even though we noticed posterior 
displacement of such structures, the vacuum of the vitrectomy 
probe and the force of the grip from the surgical forceps have 
not caused any problems in handling the posterior hyaloid, 
and the maneuver is still labeled as easy by the surgeon. This 
could vary according to the surgical skills of each surgeon; 
therefore, appropriate selection of cases should be done 
according to individual level of expertise.
Complicated diabetic tractional retinal detachment, with or 
without proliferative vitreoretinopathy, is known to be one of 
the most challenging retinal surgeries.19,30 The anatomical prog-
nosis is poor and usually accompanied by a poor visual progno-
sis due to macular involvement and extremely ischemic retinas.1 
Nevertheless, numerous recent studies have documented the 
benefits of surgical treatment of diabetic retinopathy involving 
the macula.19,31,32 Visual improvement has been reported in up 
to 75% of cases, with anatomical success ranging from 66% 
to 88%.19,31,32 Moreover, trials like the Diabetic Retinopathy 
Vitrectomy Study have found that not doing surgery can lead 
to severe visual loss (,5/200) in up to 15% of cases after one 
year and 23% after 2 years.33,34 Additionally, several large clini-
cal trials have demonstrated that certain ethnic groups (Blacks 
and Latinos) have an increased incidence of type 2 diabetes.35,36 
The Los Angeles Latino Eye Study reported that being Latino, 
especially with Mexican ascendance, poses an increased risk 
for severe, vision-threatening diabetic retinopathy, including 
proliferative stages.35,37 In this study, all the tamponades were 
made with 5000 CsT silicon oil. Although the surgeon had other 
choices, due to the severity and complexity of each particular 
case the surgeon considered the use of this silicon oil as a more 





In the present study, although anatomical success was 
obtained in all cases after surgery, only 67% remained 
attached after 3 months of follow-up. Statistical analysis 
of the best-corrected visual acuity showed a trend towards 
improvement but the change was not statistically   significant. 
The poor anatomical and visual outcomes could be explained 
by the severity of all cases along with the ethnicity of the 
sample and incidence of longstanding disease. During 
follow-up, most of the patients in whom the retina reattached 
successfully presented very pale retinas and various degrees 
of macular ischemia (data not shown).
PCL is commonly used as a tool in the surgical manage-
ment of complicated retinal detachments and proliferative 
vitreoretinopathy.38 It is easily available, easy to use, and 
has few complications.38,39 The main undesired effect is 
unintended retention either in the preretinal space (anterior 
chamber and vitreous cavity) or in the subretinal space.39 
Although there are studies that prove the safety of longstand-
ing intraocular retention, there are concerns that prolonged 
retention may cause underlying retinal pigment epithelium 
atrophy, subretinal fibrosis, and scotomas.25,26,38,40,41 The 
main risk factor for unintended retention seems to be large 
peripheral retinotomies and the absence of saline rinse after 
its removal.39 Posterior small-sized and medium-sized retinal 
breaks do not seem to increase the risk of subretinal retention 
of PCL. However, this technique was designed for patients 
with significant traction in the posterior pole and periphery, 
which may in turn increase the risk for subretinal migration 
of PCL through these retinal defects, especially during initial 
instillation of PCL in which small-sized and medium-sized 
droplets may form in the posterior pole. Nevertheless, after all 
the droplets coalesce into a single big bubble, its superficial 
tension will prevent passage through small retinal defects, 
even despite the presence of significant traction. Either way, 
a careful selection and extensive preoperative examination 
of every particular case is strongly advised.
This study has some weaknesses in addition to the small 
sample number and short follow-up time, which the authors 
would like to address. First, most of the surgical variables 
were measured subjectively, which may create a bias. A more 
appropriate approach would have been the quantification of 
indirect markers, like the number of times endodiathermy 
was needed (in the case of qualifying   bleeding), as well 
as application of validated scales for measuring   difficulty, 
like the one published by Grigorian et al, in order to have 
a more uniform group in terms of surgical difficulty.42 The 
quantification of surgical bleeding could have been done also 
by examining the vitrectomy cassette. As a matter of fact, 
the original study design contemplated examination of the 
surgical cassette as a way to assess bleeding. However,   during 
the study, we realized that some patients shared the same 
surgical cassette, making analysis impossible in this way and 
forcing us to use more subjective ways to assess bleeding. 
Second, assessment of difficulty of posterior hyaloid and 
membrane peeling was done directly by the surgeon. The 
subjective experience could vary depending on the degree of 
expertise of the surgeon and cannot be taken as an absolute 
measurement. Finally, there was an obvious selection bias 
in recruiting patients.
In summary, perfluorocarbon-perfused vitrectomy with 
23 gauge caliber and three-dimensional software is feasible, 
safe, and could help in managing difficult cases of advanced 
diabetic retinal detachments with excellent quality of visu-
alization and a hemorrhage-free environment. The physical 
properties of PCL can help in dissection of critical structures 
like the posterior hyaloid and fibrovascular membranes. 
Despite the strengths and advantages of the technique, the 
high amount of PCL needed for the realization of surgery 
prevents its routine use and, unless necessary modifications 
are made to the system, performance of further studies 
regarding this technique will be difficult.
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